Department of Gastroenterology, Govind Ballabh Pant Institute of Postgraduate Medical Education and Research (GIPMER), New Delhi, India
© Copyright 2022. Korean Association for the Study of Intestinal Diseases.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Funding Source
The authors received no financial support for the research, authorship, and/or publication of this article.
Conflict of Interest
Puri AS is an editorial board member of the journal but was not involved in the peer reviewer selection, evaluation, or decision process of this article. No other potential conflicts of interest relevant to this article were reported.
Data Availability Statement
Not applicable.
Author Contribution
Conceptualization: Puri AS, Mishra A. Data curation: Mishra A. Formal analysis: Puri AS, Sachdeva S, Dalal A. Investigation: Puri AS, Mishra A. Methodology: Puri AS, Mishra A. Project administration: Mishra A. Supervision: Puri AS. Validation: Sachdeva S, Dalal A. Visualization: Sachdeva S, Dalal A. Writing –original draft: Puri AS, Mishra A. Writing – review & editing: Puri AS, Sachdeva S, Dalal A. Approval of final manuscript: All authors.
Author (year) | Country | Study type |
No. of IBD patients |
HBV vaccine response (%) | |
---|---|---|---|---|---|
UC | CD | ||||
Vida Pérez et al. (2009) [14] | Spain | Retrospective | 45 | 55 | 34 |
Altunöz et al. (2012) [1] | Turkey | Prospective | 62 | 38 | 76 |
Gisbert et al. (2012) [15] | Spain | Prospective | 31 | 69 | 60 |
Sempere et al. (2013) [16] | Spain | Retrospective | 24 | 76 | 48 |
Andrade et al. (2015) [17] | Portugal | Prospective | 21 | 79 | 76 |
Belle et al. (2015) [18] | France | Retrospective | 20 | 80 | 79 |
Cekic et al. (2015) [19] | Turkey | Retrospective | 52 | 48 | 57 |
Cossio-Gil et al. (2015) [20] | Spain | Retrospective | 59 | 110 | 51 |
Etzion et al. (2016) [21] | Israel | RCT | 21 | 79 | 75 |
Jiang et al. (2017) [13] | China | Meta-analysis | 426 | 732 | 61 |
Chang et al. (2018) [12] | Korea | Prospective | 28 | 45 | 89 |
Pratt et al. (2018) [22] | USA | Retrospective | 137 | 246 | 55 |
Current study (2020) | India | Prospective | 100 | 0 | 82 |
Characteristics | Value (n = 100) |
---|---|
Age (yr) | 32.8 ± 11.4 |
Sex | |
Male | 59 (59) |
Female | 41 (41) |
Disease severity | |
Mild | 14 (14) |
Moderate | 69 (69) |
Severe | 17 (17) |
Disease duration (mo) | 60.3 ± 62.6 |
Extent of disease | |
E1 | 12 (12) |
E2 | 25 (25) |
E3 | 63 (63) |
Exposure to immunosuppressants | |
Corticosteroids | 64 (64) |
Azathioprine/6-MP | 64 (64) |
Biologicals | 10 (10) |
Parameter | Case group (n = 100) | Control group (n = 100) | P-value |
---|---|---|---|
Anti-HBs titer (IU/L) | 67 (16–202) | 105 (57–229) | 0.003 |
AIR (anti-HBs > 10 IU/L) | 82 (82) | 96 (96) | < 0.001 |
EIR (anti-HBs > 100 IU/L) | 41 (41) | 66 (66) | < 0.001 |
Variable | P-value |
---|---|
Sex (male vs. female) | 0.043 |
Disease duration (≤ 5 yr vs. > 5 yr) | 0.026 |
Exposure to corticosteroid | < 0.001 |
Exposure to azathioprine | 0.001 |
Exposure to biological | 0.023 |
Exposure to corticosteroid and azathioprine | < 0.001 |
Age (< 30 yr vs. > 30 yr) | 0.570 |
Severity of disease (mild to moderate vs. severe) | 0.182 |
Post first dose anti-HBs titer (≤ 2 IU/L vs. > 2 IU/L) | 0.082 |
Author (year) | Country | Study type | No. of IBD patients |
HBV vaccine response (%) | |
---|---|---|---|---|---|
UC | CD | ||||
Vida Pérez et al. (2009) [14] | Spain | Retrospective | 45 | 55 | 34 |
Altunöz et al. (2012) [1] | Turkey | Prospective | 62 | 38 | 76 |
Gisbert et al. (2012) [15] | Spain | Prospective | 31 | 69 | 60 |
Sempere et al. (2013) [16] | Spain | Retrospective | 24 | 76 | 48 |
Andrade et al. (2015) [17] | Portugal | Prospective | 21 | 79 | 76 |
Belle et al. (2015) [18] | France | Retrospective | 20 | 80 | 79 |
Cekic et al. (2015) [19] | Turkey | Retrospective | 52 | 48 | 57 |
Cossio-Gil et al. (2015) [20] | Spain | Retrospective | 59 | 110 | 51 |
Etzion et al. (2016) [21] | Israel | RCT | 21 | 79 | 75 |
Jiang et al. (2017) [13] | China | Meta-analysis | 426 | 732 | 61 |
Chang et al. (2018) [12] | Korea | Prospective | 28 | 45 | 89 |
Pratt et al. (2018) [22] | USA | Retrospective | 137 | 246 | 55 |
Current study (2020) | India | Prospective | 100 | 0 | 82 |
Valuse are presented as mean±standard deviation or number (%). 6-MP, 6-mercaptopurine.
Valuse are presented as median (interquartile range) or number (%). anti-HBs, anti-hepatitis B surface; AIR, adequate immune response; EIR, effective immune response.
anti-HBs, anti-hepatitis B surface.
HBV, hepatitis B virus; IBD, inflammatory bowel disease; UC, ulcerative colitis; CD, Crohn’s disease; RCT, randomized controlled trial.